{
    "ticker": "ARVN",
    "name": "Arvinas, Inc.",
    "description": "Arvinas, Inc. is a biopharmaceutical company that specializes in the development of targeted protein degradation therapies for the treatment of cancer and other diseases. Founded in 2013, the company leverages its proprietary technology platform, known as PROTAC (Proteolysis-Targeting Chimeras), to create innovative treatments that can selectively degrade disease-causing proteins. By harnessing the body's natural protein degradation mechanisms, Arvinas aims to provide new options for patients with limited treatment choices. The company's lead product candidates include ARV-110, aimed at prostate cancer, and ARV-471, targeting breast cancer. Arvinas is committed to advancing its pipeline of therapies through rigorous clinical trials and collaborations with other research institutions. The company is headquartered in New Haven, Connecticut, and is at the forefront of a new era in precision medicine, striving to transform the treatment landscape for cancer and other serious diseases through its groundbreaking science and technology. With a vision to improve patient outcomes and quality of life, Arvinas continues to push the boundaries of drug discovery and development, seeking to address unmet medical needs in oncology and beyond.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New Haven, Connecticut, USA",
    "founded": "2013",
    "website": "https://www.arvinas.com",
    "ceo": "John O. Schwartz",
    "social_media": {
        "twitter": "https://twitter.com/ArvinasInc",
        "linkedin": "https://www.linkedin.com/company/arvinas/"
    },
    "investor_relations": "https://ir.arvinas.com",
    "key_executives": [
        {
            "name": "John O. Schwartz",
            "position": "CEO"
        },
        {
            "name": "Craig M. Crews",
            "position": "Co-Founder and Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "ARV-110",
                "ARV-471"
            ]
        }
    ],
    "seo": {
        "meta_title": "Arvinas, Inc. | Targeted Protein Degradation Therapies",
        "meta_description": "Explore Arvinas, Inc., a leader in targeted protein degradation for cancer treatment. Learn about their innovative therapies and commitment to precision medicine.",
        "keywords": [
            "Arvinas",
            "Biotechnology",
            "Cancer Treatment",
            "Targeted Therapy",
            "PROTAC",
            "ARV-110",
            "ARV-471"
        ]
    },
    "faq": [
        {
            "question": "What does Arvinas focus on?",
            "answer": "Arvinas focuses on developing targeted protein degradation therapies for cancer and other diseases."
        },
        {
            "question": "Who is the CEO of Arvinas?",
            "answer": "John O. Schwartz is the CEO of Arvinas, Inc."
        },
        {
            "question": "Where is Arvinas headquartered?",
            "answer": "Arvinas is headquartered in New Haven, Connecticut, USA."
        },
        {
            "question": "What are Arvinas's main product candidates?",
            "answer": "Arvinas's main product candidates include ARV-110 for prostate cancer and ARV-471 for breast cancer."
        },
        {
            "question": "When was Arvinas founded?",
            "answer": "Arvinas was founded in 2013."
        }
    ],
    "competitors": [
        "BMY",
        "MRNA",
        "VRTX",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "NVS",
        "GILD",
        "PFE"
    ]
}